Xentech
|
Year Established:
2006 |
|
|
Website:
xentech.eu |
|
|
Headquarters:
Evry, , FR |
|
|
Company Type:
Small Business (1-10M TTM Revenue) |
|
|
Completed Requests:
135 |
|
|
Open Requests:
31 |
|
Certifications:
|
XenTech is an oncology preclinical CRO specializing in Patient-Derived tumor Xenografts (PDX). We test anticancer drug activity in our PDXs and identify drug response biomarkers. Cell lines derived from our PDX are available for in vitro assays and we also offer Immuno-Oncology PDX (syngeneic and PBMC humanized models) to test I/O checkpoints and combinations with existing or emerging therapies.
Our expertise :
World-renowned Breast PDX collection, extensively pubished and characterized for all DDR aspects (HRD scores, RAD51 scores, PARP inhibitor responses,…).
Special PDX range (Match-R) focusing on Acquired Resistance to the LATEST targeted Therapies (osimetinib, dabrafenib, trametinib, erdafitinib,…)
A large collection of Prostate PD models (cRPCs, …)
Media
| Site | Badges | |
|---|---|---|
| Evry 4 RUE PIERRE FONTAINE EVRY COURCOURONNES, ESSONNES, 91000 France | ||
| XENTECH 4, rue Pierre Fontaine Evry, , F 91000 France | ||
Get started
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.